Page 42«..1020..41424344..5060..»

Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023

By Dr. Matthew Watson

PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla® demand, net revenue and operating expenses.

Continue reading here:
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023

To Read More: Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
categoriaGlobal News Feed commentoComments Off on Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023 | dataApril 30th, 2023
Read All

Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023

By Dr. Matthew Watson

PALO ALTO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Henry Ji, Ph.D., Executive Chairman of Scilex, and Jaisim Shah, Chief Executive Officer and President of Scilex will participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq:

Read more:
Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023

To Read More: Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023
categoriaGlobal News Feed commentoComments Off on Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023 | dataApril 30th, 2023
Read All

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

By Dr. Matthew Watson

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 9, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer.

Link:
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

To Read More: Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
categoriaGlobal News Feed commentoComments Off on Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023 | dataApril 30th, 2023
Read All

Publication of a transparency notification received from Alychlo NV

By Dr. Matthew Watson

Liege, Belgium, 28 April 2023 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Alychlo NV, with registered offices at Lembergsesteenweg 19. 9820 Merelbeke, on 25, April 2023.

Follow this link:
Publication of a transparency notification received from Alychlo NV

To Read More: Publication of a transparency notification received from Alychlo NV
categoriaGlobal News Feed commentoComments Off on Publication of a transparency notification received from Alychlo NV | dataApril 30th, 2023
Read All

Total number of shares and voting rights in Zealand Pharma at April 28, 2023

By Dr. Matthew Watson

Company announcement – No. 18 / 2023

See the original post:
Total number of shares and voting rights in Zealand Pharma at April 28, 2023

To Read More: Total number of shares and voting rights in Zealand Pharma at April 28, 2023
categoriaGlobal News Feed commentoComments Off on Total number of shares and voting rights in Zealand Pharma at April 28, 2023 | dataApril 30th, 2023
Read All

ObsEva Annual Report 2022

By Dr. Matthew Watson

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

See the rest here:
ObsEva Annual Report 2022

To Read More: ObsEva Annual Report 2022
categoriaGlobal News Feed commentoComments Off on ObsEva Annual Report 2022 | dataApril 30th, 2023
Read All

Plus Therapeutics Announces Reverse Stock Split

By Dr. Matthew Watson

AUSTIN, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-15. The reverse stock split will become effective at 12:01 a.m. Eastern Time on May 1, 2023, and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on May 1, 2023 under the Company’s existing trading symbol, “PSTV.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 72941H509.

Here is the original post:
Plus Therapeutics Announces Reverse Stock Split

To Read More: Plus Therapeutics Announces Reverse Stock Split
categoriaGlobal News Feed commentoComments Off on Plus Therapeutics Announces Reverse Stock Split | dataApril 30th, 2023
Read All

AB Science reports its revenues for the year 2022 and provides an update on its activities

By Dr. Matthew Watson

PRESS RELEASE

See the original post:
AB Science reports its revenues for the year 2022 and provides an update on its activities

To Read More: AB Science reports its revenues for the year 2022 and provides an update on its activities
categoriaGlobal News Feed commentoComments Off on AB Science reports its revenues for the year 2022 and provides an update on its activities | dataApril 30th, 2023
Read All

Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023

By Dr. Matthew Watson

THE WOODLANDS, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Continue reading here:
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023

To Read More: Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023
categoriaGlobal News Feed commentoComments Off on Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023 | dataApril 30th, 2023
Read All

Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update

By Dr. Matthew Watson

ISTANBUL, Turkey, April 28, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.‘s (OTC: PRTT) (“Company”) President Ali Yildiz addresses the Company’s shareholders with a corporate update on expansion and forward-looking progress.

See the rest here:
Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update

To Read More: Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update
categoriaGlobal News Feed commentoComments Off on Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update | dataApril 30th, 2023
Read All

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS

By Dr. Matthew Watson

Regulated Information - Denominator

Continue reading here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS

To Read More: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
categoriaGlobal News Feed commentoComments Off on Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS | dataApril 30th, 2023
Read All

Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

By Dr. Matthew Watson

WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today  announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update.

More here:
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

To Read More: Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
categoriaGlobal News Feed commentoComments Off on Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update | dataApril 30th, 2023
Read All

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

CAMBRIDGE, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 21, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 375,000 restricted stock unit awards (RSUs) to four new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule5635(c)(4).

See more here:
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

To Read More: Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | dataApril 30th, 2023
Read All

Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older

By Dr. Matthew Watson

WESTLAKE VILLAGE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that its next-generation topical PDE4 inhibitor therapy for plaque psoriasis, ZORYVE™ (roflumilast) cream 0.3%, has received regulatory approval from Health Canada.

More:
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older

To Read More: Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
categoriaGlobal News Feed commentoComments Off on Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older | dataApril 30th, 2023
Read All

TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update

By Dr. Matthew Watson

Conference call to be held Monday, May 1, 2023, at 8:30 AM ET Conference call to be held Monday, May 1, 2023, at 8:30 AM ET

See the original post here:
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update

To Read More: TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
categoriaGlobal News Feed commentoComments Off on TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update | dataApril 30th, 2023
Read All

Preliminary Results for the Year Ended 31 December 2022

By Dr. Matthew Watson

28 April 2023

Originally posted here:
Preliminary Results for the Year Ended 31 December 2022

To Read More: Preliminary Results for the Year Ended 31 December 2022
categoriaGlobal News Feed commentoComments Off on Preliminary Results for the Year Ended 31 December 2022 | dataApril 30th, 2023
Read All

Neuronetics Announces Expanded TMS Access through United HealthCare

By Dr. Matthew Watson

UHC Medicare Advantage plans in NGS states expand access via NPPs UHC Medicare Advantage plans in NGS states expand access via NPPs

See more here:
Neuronetics Announces Expanded TMS Access through United HealthCare

To Read More: Neuronetics Announces Expanded TMS Access through United HealthCare
categoriaGlobal News Feed commentoComments Off on Neuronetics Announces Expanded TMS Access through United HealthCare | dataApril 30th, 2023
Read All

Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting

By Dr. Matthew Watson

HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual Disease (MRD) liquid biopsy assay to genitourinary (GU) cancers at the 2023 American Urological Association (AUA) Annual Meeting held in Chicago between April 28 to May 1, 2023.

Read this article:
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting

To Read More: Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting
categoriaGlobal News Feed commentoComments Off on Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting | dataApril 30th, 2023
Read All

Cronos Group Inc. to Hold Virtual 2023 Annual Meeting of Shareholders

By Dr. Matthew Watson

TORONTO, April 28, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2023 Annual Meeting of Shareholders on Thursday, June 22, 2023, at 11:00 a.m. ET.

Read the original post:
Cronos Group Inc. to Hold Virtual 2023 Annual Meeting of Shareholders

To Read More: Cronos Group Inc. to Hold Virtual 2023 Annual Meeting of Shareholders
categoriaGlobal News Feed commentoComments Off on Cronos Group Inc. to Hold Virtual 2023 Annual Meeting of Shareholders | dataApril 30th, 2023
Read All

Dividend approval

By Dr. Matthew Watson

Press release

View post:
Dividend approval

To Read More: Dividend approval
categoriaGlobal News Feed commentoComments Off on Dividend approval | dataApril 30th, 2023
Read All

Page 42«..1020..41424344..5060..»


Copyright :: 2024